EQT and KKR (KKR) announced that EQT VIII fund has agreed to sell Karo Healthcare to KKR. The acquisition marks the next chapter for Karo, as it continues to accelerate its growth strategy under KKR’s ownership, building on its transformation into one of Europe’s leading consumer health platforms since EQT’s initial investment. Karo is headquartered in Stockholm, Sweden. The transaction is subject to customary regulatory conditions and approvals and is expected to close in the coming months.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KKR:
- EQT Corporation to sell Karo Healthcare to KKR, terms undisclosed
- KKR close to deal to acquire Karo for over $2.7B, Bloomberg reports
- KKR price target lowered to $120 from $141 at Wells Fargo
- KKR price target lowered to $132 from $177 at Citi
- KKR price target lowered to $150 from $165 at Citizens JMP